GNCA News and Press, Genocea Biosciences Inc. From 02/11/21

Genocea Biosciences (GNCA): Q4 GAAP EPS of -$0.18 beats by $0.03.As of December 31, 2020, cash and cash equivalents were $79.8 million compared to $40.1 million as of December 31, 2019.Press Release For further details see: Genocea Biosciences EPS beats by $0.03

GEN-011 and GEN-009 clinical trials continue to advance ATLAS TM stimulatory antigen and inhibitory antigen (Inhibigen TM ) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell antigen discovery pr...

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcas...

Genocea Biosciences (GNCA) soars 47% premarket after highlighting the advantages of neoantigen identification with the ATLAS platform in a journal Cancer Discovery.The publication shows that ATLAS zeroes in on tumor mutations that are either neoantigens that activate ...

Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell responses CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Genoce...

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a firesid...

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview ...

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview ...

Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a n eoantigen-targeted p eripheral T cell (“NPT”)...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...